Search
Eli Lilly and Co
LLYAdd to Watchlist
1117.000USD
+9.920+0.90%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
1.05TMarket Cap
39.61P/E TTM
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Diabetes-Mounjaro
6.52B
37.02%
Diabetes-Zepbound
3.59B
20.39%
Oncology-Verzenio
1.47B
8.35%
Diabetes-Other Diabetes
1.06B
6.04%
Diabetes-Trulicity
1.05B
5.98%
Other
3.91B
22.23%
By RegionUSD
Name
Revenue
Proportion
U.S.
11.30B
64.20%
Europe
3.50B
19.87%
Other foreign countries
1.69B
9.59%
China
560.40M
3.18%
Japan
554.70M
3.15%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Diabetes-Mounjaro
6.52B
37.02%
Diabetes-Zepbound
3.59B
20.39%
Oncology-Verzenio
1.47B
8.35%
Diabetes-Other Diabetes
1.06B
6.04%
Diabetes-Trulicity
1.05B
5.98%
Other
3.91B
22.23%
